Marital Status, Living Arrangement, and Cancer Recurrence and Survival in Patients with Stage III Colon Cancer: Findings from CALGB 89803 (Alliance)

Seohyuk Lee1, Chao Ma2, Sui Zhang2, Fang-Shu Ou1, Tiffany M Bainter3, Donna Niedzwiecki4, Leonard B. Saltz5, Robert J. Mayer6, Renaud Whittom7, Alexander Hantel8, Al Benson9, Daniel Atienza10, Hedy Kindler11, Cary P. Gross12, Melinda L. Irwin13, Jeffrey A. Meyerhardt6, Charles S. Fuchs14,15

1Yale School of Medicine, New Haven, CT, USA
2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
3Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN, USA
4Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, USA
5Memorial Sloan Kettering Cancer Center, New York, NY, USA
6Department of Medical Oncology, Dana-Farber/Partners CancerCare, Boston, MA, USA
7Hôpital du Sacré-Cœur de Montréal, Montreal, Canada
8Loyola University Stritch School of Medicine, Naperville, IL, USA
9Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA
10Virginia Oncology Associates, Norfolk, VA, USA
11University of Chicago Comprehensive Cancer Center, Chicago, IL, USA
12Yale School of Medicine, Department of Internal Medicine, New Haven, CT, USA
13Yale School of Public Health, New Haven, CT, USA
14Yale Cancer Center, Smilow Cancer Hospital and Yale School of Medicine, New Haven, CT, USA
15Genentech, South San Francisco, CA, USA

Corresponding author: Charles S. Fuchs, MD, MPH, Genentech, South San Francisco, CA 94080, USA. Email: fuchs.charles.cf1@gene.com

Abstract
Background: Limited and conflicting findings have been reported regarding the association between social support and colorectal cancer (CRC) outcomes. We sought to assess the influences of marital status and living arrangement on survival outcomes among patients with stage III colon cancer.

Patients and Methods: We conducted a secondary analysis of 1082 patients with stage III colon cancer prospectively followed in the CALGB 89803 randomized adjuvant chemotherapy trial. Marital status and living arrangement were both self-reported at the time of enrollment as, respectively, married, divorced, separated, widowed, or never-married, and living alone, with a spouse or partner, with other family, in a nursing home, or other.

Results: Over a median follow-up of 7.6 years, divorced/separated/widowed patients experienced worse outcomes relative to those married regarding disease free-survival (DFS) (hazards ratio (HR), 1.44 (95% CI, 1.14-1.81); P = .002), recurrence-free survival (RFS) (HR, 1.35 (95% CI, 1.05-1.73); P = .02), and overall survival (OS) (HR, 1.40 (95% CI, 1.08-1.82); P = .01); outcomes were not significantly different for never-married patients. Compared to patients living with a spouse/partner, those living with other family experienced a DFS of 1.47 (95% CI, 1.02-2.11; P = .04), RFS of 1.34 (95% CI, 0.91-1.98; P = .14), and OS of 1.50 (95% CI, 1.00-2.25; P = .05); patients living alone did not experience significantly different outcomes.

Conclusion: Among patients with stage III colon cancer who received uniform treatment and follow-up within a nationwide randomized clinical trial, being divorced/separated/widowed and living with other family were significantly associated with greater colon cancer mortality. Interventions enhancing social support services may be clinically relevant for this patient population.

Trials Registration: ClinicalTrials.gov Identifier: NCT00003835

Key words: marital status; residence characteristics; colonic neoplasms; survival analysis; clinical trial

Implications for Practice
Interventions targeting enhancing social support services for and developing social networks in patients with colon cancer may be an important method by which the significant differences in survival across patients of varying marital statuses and living arrangements can be reduced.

Received: 12 August 2021; Accepted: 18 November 2021.

© The Author(s) 2022. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Introduction

Strong social networks have repeatedly been associated with lower total mortality, and studies examining the association between diminished social networks and mortality risk suggest relative risk estimates comparable to more traditional risk factors, including obesity, cigarette smoking, and hypertension. Marital status in particular has been suggested by some studies to be an independent prognostic factor of survival in patients with cancer, with married patients experiencing superior mortality rates compared with those divorced, separated, widowed, or never-married. Similarly, living arrangement—specifically living alone—has been observed to be associated with inferior cancer survival rates when compared with cohabiting with a spouse, significant other, or partner in some, although not all, studies.

Several studies have previously examined the influence of marital status on colorectal cancer (CRC) outcomes, but findings have been largely inconsistent. The majority of prior studies have been limited by their retrospective design and paucity of data on treatment and other confounding factors, rendering it difficult to disentangle the impact of various confounding factors from marital status or living arrangement.

We therefore sought to assess the independent influences of marital status and living arrangement on patient outcomes through secondary analysis of a prospectively-followed cohort nested in a randomized clinical trial (RCT) of adjuvant 5-fluorouracil-based therapy for stage III colon cancer. To our knowledge, this is the first prospective investigation into the impacts of marital status and living arrangement on colon cancer outcomes in North America. We additionally accounted for dietary and lifestyle factors beyond other clinical and sociodemographic variables, thereby conferring a more robust multivariable analysis. Careful and comprehensive documentation during the trial of patient performance status, pathologic stage, post-operative treatment, and diet and lifestyle habits allowed concurrent effects of patient, disease, and treatment characteristics to be examined.

Patients and Methods

Study Population

Patients in this RCT were recruited from the US and Canada as participants in the NCI-sponsored Cancer and Leukemia Group B (CALGB; now part of Alliance for Clinical Trials in Oncology) 89803 adjuvant chemotherapy trial for stage III colon cancer, comparing weekly 5-fluorouracil (5-FU) and leucovorin to weekly 5-FU, leucovorin, and irinotecan (ClinicalTrials.gov NCT0003835). One thousand two hundred sixty-four patients were enrolled between April 1999 and April 2001, after the first 87 patients of which the protocol was amended such that patients were required to complete a self-administered questionnaire examining diet and lifestyle behaviors twice: once midway through chemotherapy (approximately 4 months post-surgery; Questionnaire 1), and again 6 months following chemotherapy treatment completion (approximately 14 months post-surgery; Questionnaire 2).

Eligibility required patients to have had a complete surgical resection of the primary tumor within 56 days of trial enrollment, regional lymph node, but no distant, metastases, no prior chemotherapy or radiation treatment for the tumor, a baseline Eastern Cooperative Oncology Group (ECOG) performance status between 0 and 2, and sufficient bone marrow, hepatic, and renal functions. Fig. 1 describes the derivation of the final sample sizes of 1082 and 1069 patients included in this study for marital status and living arrangement analyses, respectively.

Assessment of Patient Marital Status, Living Arrangement, and Household Income

The marital status and living arrangement of each of the participating subjects were self-reported at the time of enrollment as, respectively, married, divorced, separated, widowed, or never-married, and living alone, with a spouse or partner, with other family, in a nursing home, or other. Analyses by living arrangement were limited to the 1069 subjects who were eligible for CALGB 89803 as described above and whose responses were specified as one of the following: living with spouse/partner, with other family (ie not a spouse/partner), or alone. Those living in a nursing home (N = 1) or other situations (N = 12) were excluded from the analysis of living arrangement due to the very small number of responders within these categories. Household income was determined by matching the zip codes of patient home addresses, self-reported at the time of enrollment, with publicly available US Census 2000 information.

Covariate Assessment

Patients completed a validated food frequency questionnaire querying consumption of 131 items over the past 3 months, as previously described. Classification of patients between prudent and Western dietary patterns—characterized by high intakes of fruits and vegetables, poultry, and fish versus high intakes of meat, fat, refined grains, and dessert,
Table 1. Baseline characteristics of 1082 patients with stage III colon cancer by marital status.

|                          | Married | Divorced/separated/widowed | Never-married | P-value* |
|--------------------------|---------|-----------------------------|---------------|---------|
| # Deaths or recurrence/at risk | #302/793 | #108/221 | #24/68 | <.001 |
| Age, median(Q1-Q3)      | 60.0 (52.0-69.0) | 64.0 (55.0-70.0) | 52.0 (43.5-61.5) | <.001 |
| Age, years, (%)         |         |                             |               |         |
| ≤60                     | 408 (51.5%) | 94 (42.5%) | 50 (73.5%) | <.001 |
| >60                     | 385 (48.5%) | 127 (57.5%) | 18 (26.5%) | <.001 |
| Sex, (%)                |         |                             |               |         |
| Male                    | 475 (59.9%) | 89 (40.3%) | 41 (60.3%) | <.001 |
| Female                  | 318 (40.1%) | 132 (59.7%) | 27 (39.7%) | <.001 |
| Race, (%)               |         |                             |               |         |
| White                   | 728 (91.8%) | 170 (76.9%) | 57 (83.8%) | <.001 |
| Other                   | 65 (8.2%) | 51 (23.1%) | 11 (16.2%) | <.001 |
| Treatment arm, (%)      |         |                             |               | .57    |
| 5-FU/LV                 | 397 (50.1%) | 119 (53.8%) | 33 (48.5%) | <.001 |
| IFL                     | 396 (49.9%) | 102 (46.2%) | 35 (51.5%) | <.001 |
| T-stage, (%)a           |         |                             |               | .05    |
| Missing                 | 17 (2.1%) | 6 (2.7%) | 3 (4.4%) | <.001 |
| T1-2                    | 114 (14.4%) | 20 (9.1%) | 5 (7.4%) | <.001 |
| T3-4                    | 662 (83.5%) | 195 (88.2%) | 60 (88.2%) | <.001 |
| Number of positive lymph nodes, (%) | | | | |
| Missing                 | 13 (1.6%) | 5 (2.3%) | 3 (4.4%) | <.001 |
| 1-3                     | 501 (63.2%) | 128 (57.9%) | 46 (67.7%) | <.001 |
| 4+                      | 279 (35.2%) | 88 (39.8%) | 19 (27.9%) | <.001 |
| Performance status, (%)b | | | | |
| Missing                 | 15 (1.9%) | 6 (2.7%) | 3 (4.4%) | <.001 |
| ECOG 0                  | 594 (74.9%) | 154 (69.7%) | 46 (67.7%) | <.001 |
| ECOG 1,2                | 184 (23.2%) | 61 (27.6%) | 19 (27.9%) | <.001 |
| Clinical bowel obstruction or perforation, no. (%) | | | | |
| No                      | 613 (77.3%) | 179 (81.0%) | 50 (73.5%) | <.001 |
| Yes                     | 180 (22.7%) | 42 (19.0%) | 18 (26.5%) | <.001 |
| Tumor location, (%)     |         |                             |               | .02    |
| Missing                 | 15 (1.9%) | 7 (3.2%) | 3 (4.4%) | <.001 |
| Distal                  | 352 (44.4%) | 74 (33.5%) | 28 (41.2%) | <.001 |
| Proximal                | 426 (53.7%) | 140 (63.4%) | 37 (54.4%) | <.001 |
| Valid FFQ1, (%)         |         |                             |               | .01    |
| No                      | 18 (2.3%) | 15 (6.8%) | 5 (7.4%) | <.001 |
| Yes                     | 775 (97.7%) | 206 (93.2%) | 63 (92.7%) | <.001 |
| Consistent aspirin use (reported use in both FFQ 1&2), no. (%) | | | | |
| No                      | 727 (91.7%) | 206 (93.2%) | 65 (95.6%) | <.001 |
| Yes                     | 66 (8.3%) | 15 (6.8%) | 3 (4.4%) | <.001 |
| BMI, (%)                |         |                             |               | .05    |
| Missing                 | 18 (2.3%) | 15 (6.8%) | 5 (7.4%) | <.001 |
| Min-24.9                | 249 (31.4%) | 73 (33.0%) | 24 (35.3%) | <.001 |
| 25-29.9                 | 302 (38.1%) | 60 (27.2%) | 17 (25.0%) | <.001 |
| 30-max                  | 224 (28.3%) | 73 (33.0%) | 22 (32.4%) | <.001 |
| Physical activity, (%)  |         |                             |               | .02    |
| Missing                 | 23 (2.9%) | 17 (7.7%) | 5 (7.4%) | <.001 |
| 0-2.9 met-h             | 283 (35.7%) | 96 (43.4%) | 28 (41.2%) | <.001 |
| 3 met-h+                | 487 (61.4%) | 108 (48.9%) | 35 (51.5%) | <.001 |
| Energy intake, (%)      |         |                             |               | .27    |
| Missing                 | 18 (2.3%) | 15 (6.8%) | 5 (7.4%) | <.001 |
| <Median                 | 387 (48.8%) | 109 (49.3%) | 26 (38.2%) | <.001 |
| ≥Median                 | 388 (48.9%) | 97 (43.9%) | 37 (54.4%) | <.001 |
Table 1. Continued

| Western dietary pattern, no. (%) | Married | Divorced/separated/widowed | Never-married | P-value* |
|----------------------------------|---------|----------------------------|---------------|----------|
| Missing                          | 18 (2.3%) | 15 (6.8%)                  | 5 (7.4%)      | .22      |
| <Median                          | 376 (47.4%) | 114 (51.6%)                | 32 (47.1%)    |          |
| ≥Median                          | 399 (50.3%) | 92 (61.6%)                 | 31 (45.6%)    |          |
| Prudent dietary pattern, no. (%) |         |                            |               |          |
| Missing                          | 18 (2.3%) | 15 (6.8%)                  | 5 (7.4%)      | .65      |
| <Median                          | 381 (48.1%) | 108 (48.9%)                | 33 (48.5%)    |          |
| ≥Median                          | 394 (49.7%) | 98 (44.3%)                 | 30 (44.1%)    |          |
| Household income, no. (%)       |         |                            |               |          |
| Missing                          | 196 (24.7%) | 42 (19.0%)                 | 17 (25.0%)    | .17      |
| <Median                          | 286 (36.1%) | 99 (44.8%)                 | 28 (41.2%)    |          |
| ≥Median                          | 311 (39.2%) | 80 (36.2%)                 | 23 (33.8%)    |          |
| Insurance status, no. (%)       |         |                            |               |          |
| Self-pay/private                 | 527 (66.5%) | 125 (56.6%)                | 47 (69.1%)    | .02      |
| Medicare/Medicaid/Military/Other | 266 (33.5%) | 96 (43.4%)                 | 21 (30.9%)    |          |

Abbreviations: 5-FU, 5-fluorouracil; LV, leucovorin; IFL, irinotecan, 5-fluorouracil, leucovorin; FFQ, food frequency questionnaire; BMI, body mass index.

respectively—was performed by following the techniques previously described. Baseline performance status; Performance status 0 = fully active; performance status 1 = restricted in physically strenuous activity but ambulatory and able to carry out light work; performance status 2 = ambulatory and capable of all self-care but unable to carry out any work activities, up and about more than 50% of waking hours.

Endpoints
The primary endpoint for this study was disease-free survival (DFS), defined as the time from study enrollment to recurrence of the tumor, the occurrence of a new primary colon cancer, or death consequent of any cause. Recurrence-free survival (RFS) was defined as the time from study enrollment to recurrence of the tumor, the occurrence of a new primary colon tumor, or death with evidence of recurrence; patients who died with no known tumor recurrence were censored at the last documented evaluation. Overall survival (OS) was defined as the time from study enrollment to death due to any cause.

Statistical Analysis
Findings from the CALGB 89803 trial for stage III colon cancer comparing adjuvant bolus 5-FU and leucovorin with the combination of bolus 5-FU, leucovorin, and irinotecan have previously been described. As the 2 chemotherapy treatment arms demonstrated similar results, patient data were combined from both treatment arms and analyzed for this study according to categories of marital status or living arrangement. Baseline characteristics were compared between patients who are married, divorced/separated/widowed, or never-married and patients living with a spouse/partner, alone, or with other family using the Wilcoxon test for continuous variables (age) and Chi-square for the remaining categorical variables.

The Kaplan-Meier method was performed to estimate the distribution of survival time according to marital status or living arrangement, and the log-rank test was conducted to compare survival between the respective subgroups. Multivariate Cox proportional hazards regression was used to determine the survival hazard ratios (HR) by marital status (married, divorced/separated/widowed, never-married) or living arrangement (with spouse/partner, alone, with other family), controlling for potential confounders. Three models were built to incrementally examine the association between marital status or living arrangement and the study endpoints. Model 1 was adjusted for age; model 2 was adjusted for age, race, sex, treatment arm, T-stage, number of positive lymph nodes, ECOG performance status, tumor location, presence of clinical bowel obstruction or perforation, consistent aspirin use, insurance status, valid FFQ1, energy intake, BMI, physical activity, Western dietary pattern, and prudent dietary pattern; where the last 5 variables were treated as time-varying covariates in the model as they were collected for and derived from both FFQ; and model 3 was adjusted for all covariates in model 2 in addition to household income, a proxy for socioeconomic status. Missing values for covariates were imputed via the following methods: (1) missing % were less than 5%, and were recoded into the majority category when used as covariates in the Cox model (T-stage, number of positive lymph nodes, performance status, and tumor location); (2) missing % were less than 5%, and were recoded into median values when used as covariates in the Cox model (BMI, physical activity, energy intake, Western dietary pattern, and prudent dietary pattern); (3) missing % was more than 5%, and was recoded as a separate indicator when used as a covariate (household income).
Tests of interaction between marital status or living arrangement and potential confounders were assessed by entering the cross-product of either variable and the covariate of interest. All statistical tests were 2-sided, and $P$ values equal to or less than .05 were considered statistically significant. All analyses were conducted using SAS software (version 9.4; SAS Institute, Cary, NC).

Patient registration and clinical data collection were managed and their analyses performed by the Alliance Statistics and Data Center. The statistical analyses were based on the study database frozen on November 9, 2009. Data quality was ensured by review of the data by the Alliance Statistics and Data Center and also by the study chairperson following Alliance policies.

All patients signed study-specific informed consent, which was approved by the NCI Cancer Treatment Evaluation Program and each participating site’s institutional review board.

**Results**

**Baseline Characteristics According to Marital Status**

Within our cohort, 73.3% of patients self-identified as married, 20.4% as divorced/separated/widowed, and 6.3% as never-married. Table 1 summarizes baseline clinical and sociodemographic characteristics of the study cohort according to marital status. Relative to married patients, divorced/separated/widowed and never-married participants were more likely to be of non-White race, present with a higher T-stage, have a much lower or higher BMI, and engage in less physical activity. Divorced/separated/widowed patients were additionally less likely to be male and have private or no insurance over public insurance, and those who had never been married were more likely to be younger.

**Association Between Marital Status and Cancer Recurrence or Mortality**

Over a median follow-up of 7.6 years, there were 434, 388, and 348 events for DFS, RFS, and OS analyses, respectively. In a Kaplan-Meier analysis, divorced/separated/widowed patients experienced an inferior DFS ($log\-rank\ P = .01$) and OS ($log\-rank\ P = .01$) relative to married and never-married patients (Fig. 2). In multivariable Cox regression analyses (Table 2), divorced/separated/widowed patients experienced worse adjusted hazard ratios (HRs) of 1.44 (95% CI, 1.14-1.81; $P = .002$) for DFS, 1.35 (95% CI, 1.05-1.73; $P = .02$) for RFS, and 1.40 (95% CI, 1.08-1.82; $P = .01$) for OS, when compared with married subjects. Never-married patients experienced similar survival rates relative to those married with a DFS of 1.00 (95% CI, 0.66-1.53; $P = .99$), RFS of 0.88 (95% CI, 0.53-1.40; $P = .59$), and OS of 1.22 (95% CI, 0.78-1.91; $P = .39$).

**Stratified Analyses of Marital Status by Potential Effect Modifiers**

We examined the influence of marital status on DFS and OS across strata of other potential predictors of patient outcome (Supplementary Tables 1 and 2). The association between marital status and patient outcome was not significantly modified across all examined strata of patient, disease, and treatment characteristics. However, in these stratified analyses, statistical power to adequately detect differences was limited by the sample size, and such analyses should be considered exploratory.

**Baseline Characteristics According to Living Arrangement**

Within our cohort, 76.4% of patients self-identified as living with a spouse/partner, 16.0% as living alone, and 7.6% as...
living with other family besides a spouse/partner. Relative to patients living with a spouse/partner, those living alone or with other family were more likely to be female, present with a higher T-stage, have a more proximal tumor, and engage in less physical activity (Table 3). Patients living with other family were also more likely to be older and of non-White race, while patients living alone were more likely to have a lower BMI.

Impact of Living Arrangement on Cancer Recurrence or Mortality

In the cohort of 1069 participants with living arrangement data, there were 427, 384, and 341 events for DFS, RFS, and OS analyses, respectively. In a Kaplan-Meier analysis, no significant differences were found in DFS (log-rank \( P = .20 \)) or OS (log-rank \( P = .11 \)) by living arrangement (Fig. 3). In multivariable Cox regression analyses, patients living with other family experienced inferior DFS and OS when compared with those living with a spouse/partner (Table 4). The fully adjusted HRs for patients living with other family were 1.47 (95% CI, 1.02-2.11; \( P = .04 \)) for DFS, 1.34 (95% CI, 0.91-1.98; \( P = .14 \)) for RFS, and 1.50 (95% CI, 1.00-2.25; \( P = .05 \)) for OS, when compared with patients living with a spouse/partner. Patients living alone experienced non-significant worse survival relative to those living with a spouse/partner with a DFS of 1.24 (95% CI, 0.96-1.61; \( P = .11 \)), RFS of 1.14 (95% CI, 0.86-1.51; \( P = .35 \)), and OS of 1.30 (95% CI, 0.98-1.73; \( P = .07 \)).

Stratified Analyses of Living Arrangement by Potential Effect Modifiers

We further examined whether the influence of living arrangement on DFS and OS differed across strata of other potential predictors of patient outcome (Supplementary Tables 3 and 4). The association between living arrangement and patient outcome was not significantly modified across all examined strata of patient, disease, and treatment characteristics. As previously mentioned, in these stratified analyses, statistical power to adequately detect differences was limited by the sample size, and such analyses should be considered exploratory.

Discussion

In this secondary analysis of prospectively-followed, resected patients with stage III colon cancer enrolled in a post-operative adjuvant chemotherapy clinical trial, we found divorced/separated/widowed patients experienced significantly worse DFS, RFS, and OS compared to those married, and patients living with other family experienced decreased DFS and OS relative to those living with a spouse/partner. The inferior patient outcomes associated with being divorced/separated/widowed and living with other family remained consistent after adjusting for multiple predictors of patient outcome and across strata of patient, disease, and treatment characteristics, including household income and dietary and lifestyle factors. Our study is, to our knowledge, the first North American prospective investigation into the associations between marital status and living arrangement and colon cancer patient outcomes.

A limited number of studies have examined these factors in patients with CRC. A few studies have reported worse cancer-specific mortality in non-married CRC patients relative to those married or among CRC patients living alone.
Table 3. Baseline characteristics of 1069 patients with stage III colon cancer by living arrangement.

|                                | With spouse/partner | Alone       | With other family | P-value |
|--------------------------------|---------------------|-------------|-------------------|---------|
| # Deaths or recurrence/at risk | #315/817            | #76/171     | #36/81            |         |
| Age, median (Q1-Q3)            | 60 (51-59)          | 64 (55-70)  | 56 (48-67)        | .0002   |
| Age, years, no. (%)            |                     |             |                   |         |
| ≤60                            | 422 (51.7%)         | 71 (41.5%)  | 52 (64.2%)        | .003    |
| >60                            | 395 (48.3%)         | 100 (58.5%) | 29 (35.8%)        |         |
| Sex, no. (%)                   |                     |             |                   |         |
| Male                           | 498 (61.0%)         | 68 (39.8%)  | 29 (35.8%)        | <.00010 |
| Female                         | 319 (39.0%)         | 103 (60.2%) | 52 (64.2%)        |         |
| Race, no. (%)                  |                     |             |                   |         |
| White                          | 750 (91.8%)         | 139 (81.3%) | 55 (67.9%)        | <.00010 |
| Other                          | 67 (8.2%)           | 32 (18.7%)  | 26 (32.1%)        |         |
| Treatment arm, no. (%)         |                     |             |                   |         |
| 5-FU/LV                        | 412 (50.4%)         | 85 (49.7%)  | 45 (55.6%)        | .65     |
| IFL                            | 405 (49.6%)         | 86 (50.3%)  | 36 (44.4%)        |         |
| T-stage, no. (%)a              |                     |             |                   |         |
| Missing                        | 19 (2.3%)           | 1 (0.58%)   | 5 (6.2%)          | .03     |
| T1-2                           | 117 (14.3%)         | 13 (7.6%)   | 7 (8.6%)          |         |
| T3-4                           | 681 (83.4%)         | 157 (91.8%) | 69 (85.2%)        |         |
| Number of positive lymph nodes, no. (%) |                 |             |                   |         |
| Missing                        | 15 (1.8%)           | 1 (0.58%)   | 4 (4.9%)          | .53     |
| 1-3                            | 514 (62.9%)         | 103 (60.2%) | 52 (64.2%)        |         |
| 4+                             | 288 (35.3%)         | 67 (39.2%)  | 25 (30.9%)        |         |
| Performance status, no. (%)b   |                     |             |                   |         |
| Missing                        | 17 (2.1%)           | 1 (0.58%)   | 5 (6.2%)          | .07     |
| ECOG 0                         | 614 (75.2%)         | 123 (71.9%) | 50 (61.7%)        |         |
| ECOG 1,2                       | 186 (22.8%)         | 47 (27.5%)  | 26 (32.1%)        |         |
| Clinical bowel obstruction or perforation, no. (%) |     |             |                   | .47     |
| No                             | 630 (77.1%)         | 139 (81.3%) | 62 (76.5%)        |         |
| Yes                            | 187 (22.9%)         | 32 (18.7%)  | 19 (23.5%)        |         |
| Tumor location, no. (%)        |                     |             |                   | .008    |
| Missing                        | 18 (2.2%)           | 2 (1.2%)    | 4 (4.9%)          |         |
| Distal                         | 365 (44.7%)         | 57 (33.3%)  | 28 (34.6%)        |         |
| Proximal                       | 434 (53.1%)         | 112 (65.5%) | 49 (60.5%)        |         |
| Consistent aspirin use (both FFQ1&2), no. (%) |     |             |                   | .34     |
| No                             | 753 (92.2%)         | 161 (94.2%) | 72 (88.9%)        |         |
| Yes                            | 64 (7.8%)           | 10 (5.8%)   | 9 (11.1%)         |         |
| BMI, no. (%)                   |                     |             |                   | .02     |
| Missing                        | 20 (2.5%)           | 9 (5.3%)    | 8 (9.8%)          |         |
| Min-24.9                       | 256 (31.3%)         | 64 (37.4%)  | 21 (25.9%)        |         |
| 25-29.9                        | 308 (37.7%)         | 47 (27.5%)  | 21 (25.9%)        |         |
| 30-max                         | 233 (28.5%)         | 51 (29.8%)  | 31 (38.3%)        |         |
| Physical activity, no. (%)     |                     |             |                   | .004    |
| Missing                        | 25 (3.1%)           | 11 (6.4%)   | 8 (9.9%)          |         |
| 0-2.9 met-h                    | 290 (35.5%)         | 75 (43.9%)  | 38 (46.9%)        |         |
| 3 met-h+                       | 502 (61.4%)         | 85 (49.7%)  | 35 (43.2%)        |         |
| Energy intake, no. (%)         |                     |             |                   | .51     |
| Missing                        | 20 (2.5%)           | 9 (5.3%)    | 8 (9.9%)          |         |
| <Median                        | 393 (48.1%)         | 88 (51.5%)  | 37 (45.7%)        |         |
| ≥Median                        | 404 (49.5%)         | 74 (43.3%)  | 36 (44.4%)        |         |
surveillance\textsuperscript{37} or DNA damage\textsuperscript{38}; indeed, a higher allostatic load of cancer, chronic stress may result in impaired tumor immune has been associated with increased overall cancer-specific mortality.\textsuperscript{39,40} Among patients with breast cancer, it has recently also been correlated with worse chemotherapy completion rates.\textsuperscript{41}

Table 3. Continued

|                                  | With spouse/partner | Alone     | With other family | $P$-value |
|----------------------------------|---------------------|-----------|-------------------|-----------|
| Western dietary pattern, no. (%) |                     |           |                   |           |
| Missing                          | 20 (2.5%)           | 9 (5.3%)  | 8 (9.9%)          | .26       |
| $<$Median                        | 389 (47.6%)         | 89 (542.1%)| 40 (49.4%)        |           |
| $\geq$Median                     | 408 (49.9%)         | 73 (42.7%)| 33 (40.7%)        |           |
| Prudent dietary pattern, no. (%) |                     |           |                   |           |
| Missing                          | 20 (2.5%)           | 9 (5.3%)  | 8 (9.9%)          | .92       |
| $<$Median                        | 395 (48.4%)         | 83 (48.5%)| 36 (44.4%)        |           |
| $\geq$Median                     | 402 (49.2%)         | 79 (46.2%)| 37 (45.7%)        |           |
| Household income, no. (%)        |                     |           |                   |           |
| Missing                          | 203 (24.9%)         | 35 (20.5%)| 12 (14.8%)        | .07       |
| $<$Median                        | 292 (35.7%)         | 73 (42.7%)| 42 (51.9%)        |           |
| $\geq$Median                     | 322 (39.4%)         | 63 (36.8%)| 27 (33.3%)        |           |
| Insurance status, no. (%)        |                     |           |                   |           |
| Self-pay/private                 | 539 (66.0%)         | 99 (57.9%)| 54 (66.7%)        | .12       |
| Medicare/Medicaid/Military/Other | 278 (34.0%)         | 72 (42.1%)| 27 (33.3%)        |           |

Abbreviations: 5-FU = 5-fluorouracil; LV = leucovorin; IFL = irinotecan, 5-fluorouracil, leucovorin; FFQ = food frequency questionnaire; BMI = body mass index.

$^*$T1-2 = level of invasion through the bowel wall not beyond the muscle layer; T3-4 = level of invasion through the bowel wall beyond the muscle layer.

$^*$Baseline performance status: performance status 0 = fully active; performance status 1 = restricted in physically strenuous activity but ambulatory and able to carry out light work; performance status 2 = ambulatory and capable of all self-care but unable to carry out any work activities, up and about more than 50% of waking hours.

$^*$P-value based on (1) Wilcoxon test for continuous variable (age); or (2) Chi-square test for categorical variables.

compared to those living with someone.\textsuperscript{14,15} In contrast, other studies have reported mixed or non-significant associations between marital status and CRC outcomes.\textsuperscript{13,22,24} These studies were, however, mostly conducted with northern European patient populations, and international differences in cultural and social dynamics between current and past spouses/partners may have resulted in these discrepant findings. Indeed, a recent US-based SEER investigation showed that cancer-specific survival has drastically improved since 1990 for patients of all marital statuses except for those widowed.\textsuperscript{23} Studies of patients diagnosed with malignancies other than CRC have also reported inferior outcomes among divorced, separated, and widowed patients when compared with those married or never-married.\textsuperscript{12,17,18,33,34}

It is important to note the growing body of literature suggesting an association between greater allostatic burden—the cumulative biological burden of chronic stress experienced during life—and worse health outcomes via dysregulation of cardiovascular, immune, and metabolic systems.\textsuperscript{35,36} In the context of cancer, chronic stress may result in impaired tumor immune surveillance\textsuperscript{37} or DNA damage;\textsuperscript{38} indeed, a higher allostatic load has been associated with increased overall cancer-specific mortality.\textsuperscript{39,40} Among patients with breast cancer, it has recently also been correlated with worse chemotherapy completion rates.\textsuperscript{41} Although no studies to date have examined the role of allostatic load in CRC outcomes, our finding that disruptions in or loss of relationships—as is the case in divorce, separation, and widowhood—are associated with worse survival, rather than never having been married, may be supportive of this notion. Future research should additionally address the role of allostatic load in influencing patient outcomes.

With respect to living arrangement, we found that patients residing with other family experienced inferior outcomes when compared with those living with a spouse or partner. Although patients in our cohort who were living with other family were more likely to be obese, engage in less physical activity, present with a worse performances status, and possess a lower household income, our results remained largely unchanged, even after adjusting for these factors. Despite adjusting for these variables in our analyses, residual confounding or additional confounding by comorbidities may have contributed to the observed worse outcomes in this group. The meaning of this finding is ultimately less clear, but may be attributable to the other family members these patients were living with potentially being dependent whose care or rearing the patients may have prioritized over their own recovery.

Our overall findings lend support for the general hypothesis that stronger social networks are associated with improved outcomes among colon cancer patients. A variety of mechanisms have been proposed to contribute to the better outcomes observed in cancer patients with greater social support. Married patients are more likely to present at an earlier stage, undergo more definitive treatment, demonstrate greater treatment adherence, and receive any treatment at all.\textsuperscript{9,11,16} Potentially due to the behavior- and health-monitoring influences conferred by having a spouse,\textsuperscript{42,43} Social networks and living situations can influence dietary and lifestyle factors, and such behaviors have long been demonstrated to influence both CRC risk and outcomes.\textsuperscript{44,46} However, in the current study, we observed significant associations between both marital status and living arrangement and patient outcome even after adjusting for prospectively-collected data on dietary and lifestyle factors as well as median household income. As the nature and quality of treatment were standardized across our entire cohort of all same-stage patients, our results offer some evidence for the notion that psychosocial support garnered through social networks can influence cancer patient outcomes.
Assessing relationships between marital status or living arrangement and patient outcomes in colon cancer through an RCT offers several strengths. By studying patients enrolled in a clinical trial, we potentially reduced the biases introduced by differences in access to healthcare resources unavoidable in population-based cancer registries. Moreover, as all patients in this study met the same enrollment criteria and received adjuvant 5-FU-based chemotherapy, confounding by patient characteristics or the nature of therapy was minimized. Finally, all patients had stage III colon cancer, minimizing the effect of disease stage heterogeneity on outcomes.

Our study is not without limitations. Patients who choose to enroll in clinical trials may differ from the general population: they must meet specific eligibility criteria, be chosen as appropriate candidates, and have the motivation to participate. Nonetheless, the overall outcomes for patients in this trial were comparable to those of a similarly staged population in the SEER database. Moreover, CALGB 89803 enrolled patients from both community and academic centers across North America, thereby lowering the likelihood of biased sampling, and the cohort appears to have characteristics representative of the larger population of patients with stage III colon cancer. Marital status and living arrangement were also noted only at the time of trial enrollment. Although any changes during the trial or follow-up period would therefore have been missed, incorporation of such changes—at least with respect to marital status—has been shown in some cases to paradoxically decrease the observed benefits of marriage. Furthermore, household income was determined indirectly using zip codes and publicly available US census data as a proxy. Despite these values thus reflecting the median income of each patient’s neighborhood, this is a well-established methodology and unlikely to have significantly confounded our results. The presence of residual confounding cannot be excluded; however, our findings remained consistent even after controlling for both known and suspected patient outcome predictors. Additional confounding by comorbidities may have still contributed to the observed worse outcomes among patients residing with other family or those who were divorced/separated/widowed, although enrollment into this RCT was restricted to patients with a relatively normal baseline ECOG performance status. Lastly, the data collection for the original RCT was performed during a time when marriage was not available to same-sex couples living in the US, and our findings relating to marital status may thus not be generalizable to individuals in non-heterosexual relationships.

Conclusion

In conclusion, we found being divorced/separated/widowed or living with other family were significantly associated with worse colon cancer recurrence and mortality—relative to being married or living with a spouse/partner, respectively—in this cohort of patients with stage III colon cancer treated within an RCT. National US census data from the 2018 Current Population Survey Annual Social and Economic Supplement indicate temporal trends of increasingly delayed age at first marriage and greater prevalence of single-person households. Americans are also now almost 3 times more likely than in the past to report having no one in their lives with whom they can discuss serious matters. Interventions targeting enhancing social support services and developing social networks in patients with colon cancer may be an important method by which the significant differences in survival across patients of varying marital statuses and living arrangements can be reduced.
Table 4. Living arrangement, colon cancer recurrence, and mortality.

| Disease-free survival | With spouse/partner | Alone | Other family |
|-----------------------|---------------------|-------|--------------|
|                       | Event/at risk       | #315/817 | #76/171 | #36/81 |
| Age-adjusted only, HR (95% CI) | Ref | 1.17 (0.91-1.51) | .22 | 1.29 (0.91-1.82) | .15 |
| Multivariable adjusted, HR (95% CI) | Ref | 1.24 (0.96-1.61) | .10 | 1.45 (1.01-2.08) | .05 |
| Multivariable adjusted, HR (95% CI) | Ref | 1.24 (0.96-1.61) | .11 | 1.47 (1.02-2.11) | .04 |

| Overall survival | Event/at risk | #248/817 | #64/171 | #29/81 |
|------------------|--------------|----------|---------|-------|
| Age-adjusted only, HR (95% CI) | Ref | 1.25 (0.95-1.64) | .12 | 1.35 (0.92-1.99) | .13 |
| Multivariable adjusted, HR (95% CI) | Ref | 1.31 (0.98-1.74) | .06 | 1.47 (0.98-2.21) | .06 |
| Multivariable adjusted, HR (95% CI) | Ref | 1.30 (0.98-1.73) | .07 | 1.50 (1.00-2.25) | .05 |

A chi-square goodness of fit test with P < .001 suggested significant difference between 3 levels of living arrangement.

Funding
Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Numbers U10CA180821, U10CA180882 and U24CA196171 (to the Alliance for Clinical Trials in Oncology), UG1CA233180, UG1CA233327, UG1CA198958, UG1CA233290, U10CA180867, U10CA138561, U10CA180791, UG1CA233337, R01CA149222, and P30CA016359; U10CA180888 (SWOG); U10CA180820 and UG1CA233320 (ECOG-ACRIN). https://acknowledgments.alliancefound.org. J.A.M. research is supported by the Douglas Gray Woodruff Chair fund, the Guo Shu Shi Fund, Anonymous Family Fund for Innovations in Colorectal Cancer, Project P fund, and the George Stone Family Foundation. Also supported in part by funds from Pharmacia & Upjohn Company (now Pfizer Oncology; to C.S. Fuchs), the Stand-Up-to-Cancer Colorectal Cancer Dream Team (C.S. Fuchs, Grant Number: SU2C-AACR-DT22-17), NIH R01 CA169141, NIH R01 CA18553, and NIH P50 CA127003 to C.S. Fuchs. Stand Up To Cancer is a division of the Entertainment Industry Foundation. Research grants are administered by the American Association for Cancer Research, the Scientific Partner of SU2C. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Conflicts of Interest
Charles Fuchs: Agios, Amylin Pharmaceuticals, AstraZeneca, Bain Capital, CytomX Therapeutics, Daiichi-Sankyo, Eli Lilly, Entrinsic Health, Evolveimmune Therapeutics, Genentech, Merck, Taiho, Unum Therapeutics (C/A); Amylin Pharmaceuticals, Eli Lilly (ET), CytomX, Entrinsic Health, Evolveimmune Therapeutics (OI), Genentech (E, OI), CytomX Therapeutics, Evolveimmune Therapeutic (Other—leadership); Renaud Whitton: AstraZeneca Canada, Roche Canada (C/A); Al Benson: Abbvie, Apexigen, Array BioPharma, Artemida, Bristol-Myers Squibb, HalioDx, Infinity Pharmaceuticals, Janssen Oncology, Merck Sharp & Dohme, Natera, Pfizer, Samsung Bioepis, Therabion, Xencor (C/A), Amgen, Astellas Pharma, Bristol-Myers Squibb, Celgene, Elevar Therapeutics, Inc, ITM-LET-01—Isotopen Technologien München, ITM Solucin GmbH, MedImmune, Merck Sharp & Dohme, Rafael Pharmaceuticals, Inc, ST Pharm Co., Ltd., Syncore, Mirati, Taiho Pharmaceutical, Tyme Inc, Xencor (RF); Cary P. Gross: Johnson and Johnson (C/A), AstraZeneca, Genentech, NCCN (RF); Jeffrey Meyerhardt: COTA Healthcare (C/A), Boston Biomedical (RF—inst), Taiho Pharmaceutical (Other—NCCN grant review panel). The other authors have no relevant conflicts of interest.

Author Contributions
Conception/design: C.F. Provision of study material or patients: C.F., J.M. Collection and/or assembly of data: C.M., S.Z. Data analysis and interpretation: C.F., S.L., C.M., S.Z.,
F.-S.O., T.B. Manuscript writing: C.F., S.L. Final approval of manuscript: All authors

Data Availability
The data underlying this article will be shared on reasonable request to the corresponding author.

Supplementary Material
Supplementary material is available at The Oncologist online.

References
1. House JS, Landis KR, Umberson D. Social relationships and health. Science. 1988;241(4865):540-545.
2. Kawachi I, Colditz GA, Ascherio A, et al. A prospective study of social networks in relation to total mortality and cardiovascular disease in men in the USA. J Epidemiol Community Health. 1996;50(3):245-251.
3. Holt-Lunstad J, Smith TB, Layton JB. Social relationships and mortality risk: a meta-analytic review. PLoS Med. 2010;7(7):e1000316.
4. Berkman LF. The role of social relations in health promotion. Psychosom Med. 1995;57(3):243-254.
5. Pantell M, Rehkopf D, Jutte D, Syme SL, Balmes J, Adler N. Social isolation: a predictor of mortality comparable to traditional clinical risk factors. Am J Public Health. 2013;103(11):2056-2062.
6. Fossi SD, Cvanarova M, Chen L, et al. Adverse prognostic factors for testicular cancer-specific survival: a population-based study of 27,948 patients. J Clin Oncol. 2011;29(8):963-970.
7. Baine M, Sahak F, Lin C, Chakraborty S, Lyden E, Batra SK. Marital status and survival in pancreatic cancer patients: a SEER based analysis. PLoS One. 2011;6(6):e21052.
8. Mahdi H, Kumar S, Munkarah AR, Abdalamm M, Doherty M, Swensen R. Prognostic impact of marital status on survival of women with epithelial ovarian cancer. Psychooncology. 2013;22(1):83-88.
9. Aizer AA, Chen MH, McCarthy EP, et al. Marital status and survival in patients with cancer. J Clin Oncol. 2013;31(31):3869-3876.
10. Krongrad A, Lai H, Burke MA, Goodkin K, Lai S. Marriage and 12. changes in health-related quality of life in patients with colorectal cancer. J Clin Oncol. 2010;198(3):612-617.
11. Li Q, Gan L, Liang L, Li X, Cai S. The influence of marital status on stage at diagnosis and survival of patients with colorectal cancer. Oncotarget. 2015;6(9):7339-7347.
12. Wang L, Wilson SE, Stewart DB, Hovenbeck AS. Marital status and colon cancer outcomes in US Surveillance, Epidemiology and End Results registries: does marriage affect cancer survival by gender and stage? Cancer Epidemiol. 2011;35(5):417-422.
13. Fung Y, Dai W, Li Y, Mo S, Li Q, Cai S. The effect of marital status by age on patients with colorectal cancer over the past decades: a SEER-based analysis. Int J Colorectal Dis. 2018;33(8):1001-1010.
14. Johansen C, Schou G, Soll-Johanning H, Mellemgaard A, Lynge E. Influence of marital status on survival from colon and rectal cancer in Denmark. Br J Cancer. 1996;74(6):985-988.
15. Meyerhardt JA, Heseltine D, Campos H, et al. Assessment of a dietary questionnaire in cancer patients receiving cytotoxic chemotherapy. J Clin Oncol. 2005;23(33):8453-8460.
16. Rimm EB, Giovannucci EL, Stampfer MJ, Colditz GA, Litin LB, Willett WC. Reproducibility and validity of an expanded self-administered semiquantitative food frequency questionnaire among male health professionals. Am J Epidemiol. 1992;135(10):1114-1126.
17. Saltz LB, Niedzwiecki D, Hollis D, et al. Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. JAMA. 2007;298(7):754-764.
18. Fung TT, Kashambwa R, Sato K, et al. Post diagnosis diet quality and colorectal cancer survival in women. PLoS One. 2014;9(12):e113577.
19. Allostatic Load in Cancer: A Systematic Review and Mini Meta-Analysis. Psychother Psychosom. 2021;90(1):112-127.
20. Allostatic Load and Its Impact on Health: A Systematic Review. Psychol Med. 2018;54:119-124.
21. Seeman TE, McClewen BS, Rowe JW, Singer BH. Allostatic load as a marker of cumulative biological risk: MacArthur studies of successful aging. Proc Natl Acad Sci USA. 2001;98(8):4770-4775.
22. Guidi J, Lucente M, Sonino N, Fava GA. Allostatic Load in Cancer: A Systematic Review and Mini Meta-Analysis. J Clin Oncol. 2021;6(9):7339-7347.
23. Leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89030. J Clin Oncol. 2007;25(23):3456-3461.
24. Psoriasis has a marker of cumulative biological risk: MacArthur studies of successful aging. J Clin Oncol. 2012;30(7):189-194.
25. Goodwin JS, Hunt WC, Key CR, Samet JM. The effect of marital status on stage, treatment, and survival of cancer patients. JAMA. 1987;258(21):3125-3130.
26. Nelles JL, Joseph SA, Konety BR. The impact of marriage on bladder cancer mortality. Urol Oncol. 2009;27(3):263-267.
27. Reyes Ortiz CA, Freeman JL, Kuo YF, Goodwin JS. The influence of marital status on stage at diagnosis and survival of older persons with melanoma. J Gerontol A Biol Sci Med Sci. 2007;62(8):892-898.
28. Akinyemiju T, Wilson LE, Deveaux A, et al. Association of allostatic load with all-cause andcancer mortality by race and body mass index in theregards cohort. Cancers (Basel) 2020;12:1695.
41. American Association for Cancer Research. Chronic stress may impact treatment completion and survival outcomes in patients with breast cancer. 2021. Available at https://www.aacr.org/about-the-aacr/newsroom/news-releases/chronic-stress-may-impact-treatment-completion-and-survival-outcomes-in-patients-with-breast-cancer/. Accessed October 16, 2021.

42. Umberson D. Gender, marital status and the social control of health behavior. Soc Sci Med. 1992;34(8):907-917.

43. Aizer AA, Paly JJ, Zietman AL, et al. Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. J Clin Oncol. 2012;30(25):3071-3076.

44. Meyerhardt JA, Giovannucci EL, Holmes MD, et al. Physical activity and survival after colorectal cancer diagnosis. J Clin Oncol. 2006;24(22):3527-3534.

45. Schmid D, Leitzmann MF. Association between physical activity and mortality among breast cancer and colorectal cancer survivors: a systematic review and meta-analysis. Ann Oncol. 2014;25(7):1293-1311.

46. Lee KJ, Inoue M, Otani T, Iwasaki M, Sasazuki S, Tsugane S; JPHC Study Group. Physical activity and risk of colorectal cancer in Japanese men and women: the Japan Public Health Center-based prospective study. Cancer Causes Control. 2007;18(2):199-209.

47. Korenman S, Goldman N, Fu H. Misclassification bias in estimates of bereavement effects. Am J Epidemiol. 1997;145(11):995-1002.

48. United States Census Bureau. 2018 Current Population Survey Annual Social and Economic Supplement. https://www.census.gov/data/datasets/2018/demo/cps/cps-asec-2018.html.

49. McPherson M, Smith-Lovin L, Brashears ME. Social isolation in America: changes in core discussion networks over two decades. American Sociological Review. 2006;71(3):353-375.